Exosens Shares Retreat Midday After High Volatility
Exosens stock falls by 2.85% this Tuesday, December 16, 2025, at midday, settling at 44.30 euros compared to 45.60 euros the previous day. This correction follows several consecutive sessions of increase after securing a historic contract with the German army.
Midday Trading Update
The French defense optronics specialist shows a decline of 2.85% in mid-session trading, bringing the price to 44.30 euros. Trading volumes remain moderate with 0.07% of capital traded, indicating a measured profit-taking after last Thursday's surge of over 7% following the announcement of the mega-contract. Over the week, the stock now shows a decline of 8.19%, but still maintains an exceptional annual performance of 152.4%, significantly outperforming the CAC 40. On December 10, Exosens unveiled a 500 million euro contract to supply 200,000 light intensifying tubes for Theon International's Mikron night vision binoculars, intended for the German and Belgian armies, with deliveries scheduled between 2027 and 2029. JPMorgan responded by raising its price target from 54 to 60 euros on December 10, maintaining its overweight recommendation, while BNP Paribas had already raised its target to 49 euros at the beginning of December.
Technical Indicators and Market Reaction
The Relative Strength Index (RSI) stands at 64, nearing the overbought zone at 70, suggesting short-term caution after recent strong gains. The price is slightly below its 50-day moving average calculated at 45.85 euros, confirming a technical breathing phase. The MACD indicator shows contradictory signals with a positive histogram at 0.47 and a Signal Line at -0.05, indicating market hesitation. The stock encounters technical resistance identified at 48.90 euros, a level the price has not managed to sustainably surpass in previous sessions. The support at 41 euros provides a considerable safety margin in case of further corrections. The upper Bollinger band, set at 49.66 euros, also represents a near technical ceiling. With a monthly volatility of 14.30 and a beta of 0.29, Exosens shows a relative decorrelation from the CAC 40, evolving according to its own sector dynamics in a context of strong European demand for defense equipment.
Fundamentals Remain Strong Despite Today's Correction
Beyond today's correction, the fundamentals remain particularly strong. The contract announced on December 10 is part of the extension until 2030 of the commercial agreement between Exosens and Theon, secured on December 3, covering the supply of over 400,000 light intensifying tubes. This visibility strengthens the group's position in a market where global demand consistently exceeds supply, particularly in Europe amid geopolitical tensions. In the first nine months of 2025, Exosens recorded a revenue growth of 23.2% to 327.8 million euros, confirming the favorable dynamics of the defense sector. The group maintains its annual targets with revenue growth expected at the high end of the 15 to 20% range and an adjusted EBITDA increase at the lower end of the 20 to 25% range. This session of technical consolidation does not alter the medium-term prospects of the French specialist, who benefits from a supportive environment and a robust order book until 2029.
